BCTX — BriaCell Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1610820 ·
Last close
$4.32
Market Cap
$37.58M
52W High
$14.68
52W Low
$2.60
ADV30
467,063
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -7,620,794 | -7,164,507 | 27,071,310 | 6,880,221 | 3,662,350 |
| Jan 2026 | 0 | — | -7,531,266 | -7,221,820 | 33,594,454 | 29,903,628 | 3,380,646 |
| Oct 2025 | 0 | — | -8,322,943 | -8,197,565 | 13,075,050 | 2,714,012 | 3,724,646 |
| Apr 2025 | 0 | — | -6,328,255 | -6,126,902 | 17,001,798 | 12,460,253 | 5,060,645 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,855,229
Investing CF
$-8,900,576
Financing CF
$42,588,817
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-24.34
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-134,339,456
Inventory
—
Receivables
$2,588,749
ST Investments
$15,924,204
EBIT TTM
$-29,249,583
Pretax Income TTM
$-29,037,205
Interest Exp TTM
$66,610
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2025 | — | — | — | — | — | — | — |
| Jul 2024 | 0 | -33,330,076 | -4,791,466 | 5,872,261 | 8,557,193 | -2,382,410 | -24,126,128 |
| Jul 2023 | 0 | -23,272,264 | -20,302,394 | 27,163,577 | 30,940,758 | -3,777,181 | -23,744,860 |
| Jul 2022 | 0 | -15,285,553 | -26,838,903 | 42,577,041 | 32,248,109 | 10,328,932 | -12,484,376 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATNM | Actinium Pharmaceuticals, Inc. | $37.73M | $1.20 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $37.82M | $0.90 | — |
| IMMP | IMMUTEP Ltd | $38.32M | $0.26 | — |
| CRVO | CervoMed Inc. | $38.40M | $2.54 | — |
| NNVC | NANOVIRICIDES, INC. | $36.76M | $1.44 | — |
News headlines (Yahoo Finance, 1h cache)
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
2026-09-14 11:30 · Yahoo
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
2026-09-08 11:30 · Yahoo
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
2026-07-16 11:30 · Yahoo
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
2026-07-15 11:30 · Yahoo
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
2026-07-07 11:30 · Yahoo
BriaCell Presents Positive Clinical Data at ASCO 2026
2026-06-01 11:30 · Yahoo
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
2026-05-26 11:30 · Yahoo
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
2026-05-22 11:30 · Yahoo
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
2026-05-15 11:30 · Yahoo
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
2026-05-14 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.